Proper psychosocial rehabilitation for stabilised patients with schizophrenia: The role of new therapies

European Neuropsychopharmacology

Volumn 6, Issue SUPPL.2, 1996, Pages

  Peuskens, Joseph ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Chronic schizophrenia; Cognitive remediation; Family therapy; Psychosocial rehabilitation; Risperidonc; Vulnerability stress model

Indexed keywords

RISPERIDONE;

COGNITION; CONFERENCE PAPER; FAMILY THERAPY; HUMAN; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; REHABILITATION; SCHIZOPHRENIA; ARTICLE; PSYCHOLOGY; SOCIAL SUPPORT;

FAMILY THERAPY; HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIAL SUPPORT;

EID: 0029896051     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Addington, D.E., Jones, B., Blood. D., Chouinard, G., Remington, G. and Albright, P. (1993) Reduction of hospital days in chronic schizophrenic patients treated with rispendone: A retrospective study. Clin. Ther. 15, 417-425.
2. Bachrach, L.L. (1992) Psychosocial rehabilitation and psychiatry in the care of long-term patients. Am. J. Psychiatr. 149, 1455-1463.
3. Barrowclough, C. and Tamer, N. (1992) Interventions with families. In Birchwood, M. and Tamer, N. (Eds), Innovations in the psychological management of schizophrenia. John Wiley, Chichester, pp. 74-102.
4. Bennett, D. (1983) The historical development of rehabilitation services. In Watts, F.N. and Bennett D.H. (Eds), Theory and practice of psychiatric rehabilitation. John Wiley. Chichester. pp. 15.
5. Brenner, H.D., Hodel, B., Juhe, G. and Roder V. (1987) Kognitive Therapie bei Schizophrenen: Problem analyse und empirische Ergebnisse. Nervenarzt 58, 72-83.
6. Carman, J., Peuskens, J. and Vangeneugden T. (1995) Rispendone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int. Clin. Psychopharmacol. 10, 207-213.
7. Crow, T.J., MacMillan, J.F., Johnson, A.L. and Johnstone, E.C. (1986) A randomized controlled trial of prophylactic neuroleptic treatment. Br. J. Psychiatr. 148, 120-127.
8. Fleischhacker, W.W., Meise, V., Gunther, V. and Kurz, M. (1994) Compliance with antipsychotic drug treatment: influence in side effects. Acta Psychiatr. Scand. 89 (Suppl. 382), 11-15.
9. Gallhofer, B. (1995) Cognitive dysfunction in schizophrenia: comparison of treatment with a novel antipsychotic agent vs. conventional neuroleptic drugs, Eur, Neuropsychopharmacol. 5, 200-201.
10. Goldberg, T.E. and Weinberger, D.R. (1994) The effects of clozapine on neurocognition: an overview. J. Clin. Psychiatr. 55 (4 Suppl. B), 88-90.
11. Hodel, B, and Brermer, H.D. (1994) Cognitive therapy with schizophrenic patients: conceptual basis, present state, future directions. Acta Psychiatr. Scand. 90 (Suppl. 384), 108-115.
12. Hogarty, G., Anderson, C., Reiss, D. et al. (1986) Family psychoeducation, social skills training and maintenance chemotherapy in the aftercare treatment of schizophrenia. I: one-year effects of a controlled study on relapse and expressed emotion. Arch. Gen. Psychiatr. 43, 633-642.
13. Johnson, D.A.W., Pasterski, G., Ludlow, J.M., Street, K. and Taylor. R.D.W. (1983) The discontinuance of maintenance neuroleptic therapy in chronic schizophrenia patients: drug and social consequences. Acta Psychiatr. Scand. 67, 334-352.
14. Kane, J.M., Satferman, A.Z., Pollack, S., Johns, C., Szymanski, S., Kronig, M. and Lieberman, J.A. (1994) Clozapine, negative symptoms and extrapyramidal side effects. J. Clin. Psychiatr. 55 (9 Suppl. B), 74-81.
15. Kingdon, D. and Turkington, D. (1994) Cognitive-behavioural therapy of schizophrenia. Lawrence Erlbaum Associates, Hove.
16. Kissling, W. (1994a) Duration of neuroleplic maintenance treatment. In: Kissling, W. (Ed.), Guideline for neuroleptic relapse prevention in schizophrenia. Springer Verlag, London, pp. 44-112.
17. Kissling, W. (1994b) Compliance, quality assurance and standards for relapse prevention in schizophrenia. Acta Psychiatr. Scand. 89 (Suppl. 82). 16-24.
18. Lamb, H.R. (1982) Treating the long-term mentally ill: beyond demstitutionalization. Jossey-Bass. San Francisco.
19. Leff, J. (1991) Schizophrenia: social influences on onset and relapse In: Bennett, D. and Freeman, H. (Eds.). Community Psychiatry. Churchill Livingstone. Edinburgh, pp. 189-214.
20. Leff, J. (1995) Social and psychological approaches to schizophrenia. Schizophr. Rev 3 (Suppl. 1). 20-21.
21. Liherman, R.P. (1986a) Social and independent living skills: medication-management module. McNeil Pharmaceutical. Los Angeles, CA.
22. Liberman, R.P., Mueser, K.T. and Wallace, C.J. (1986b) Social skills training tor schizophrenic individuals at risk for relapse. Am. J. Psychiatr. 143, 523-526.
23. Lieberman, J., Jody, D. Geisler, S. et al. (1993) Time course and biological correlates of treatment response in first-episode schizophrenia. Arch. Gen. Psychiatr. 50, 369-376.
24. Lindstrom, E., von Knorring, L. and Eberhand, G. (1994) Studies of selected outcome-related clinical parameters following short-term and long-term treatment with rispendone. XIXth C.I.N.P. Congress, Washington, DC.
25. Loebel, A.D., Lieberman, J.A., Alvin, J.M. et al. (1992) Duration of psychosis and outcome in first-episode sehizophrema. Am. J. Psychiatr. 149, 1183-1188.
26. Meltzer, H.Y. (1993) New drugs for the treatment of schizophrenia. Psychiatr. Clin. North Am. 16, 365-385.
27. Meltzer, H.Y. and Okayh, G. (1995) Reduction of suicidality during clozapine treatment of neuroleptic-resistaiit schizophrenia: impact on risk benefit assessment. Am J. Psychiatr. 152, 183-190.
28. Myung, A.L., Thomson, P.A. and Meltzer, H.Y. (1994) Effects of clozapine on cognitive function in schizophrenia. J. Clin. Psychiatr. 55 (9 Suppl. B), 82-87
29. Nuechterlcin, K.H. and Dawson, M.E. (1984) A heurtstic vulnerability stress model of schizophremc episodes. Schizophr. Bull. 10, 300-312.
30. Perris, C. and Skagerlind, L. (1994) Cognitive therapy with schizophrenic patients. Acta Psychiatr. Scand. 89 (Suppl. 382), 65-70.
31. Roy, A. (1986) Depression, attempted suicide, and suicide in patients with chronic schizophienia. Psychiatr. Clin. North Am. 9, 193-204.
32. Schooler, N.R. (1991) Maintenance medication for schizophienia: strategies for dose reduction Schizophr. Bull. 17, 311-324.
33. Shepherd, G. (1984) Institutional care and rehabilitation. Longman, London.
34. Stevens, B.C. (1973) Role of fluphenazine decanoate in lessening the burden ot chronic schizophrenics on the community. Psychol. Med. 3, 141-158.
35. Tarrier, N. (1994) Management and modification of residual positive psychotic symptoms. In Birchwood, M. and Tarrier, N. (Eds.), Psychological management of schizophrenia. John Wiley. London, pp. 109-132.
36. Torrey, E.F. (1983) Surviving schizophrenia: a family manual. Harper Row, New York, NY, pp. 112.
37. Vaccaro, J.V. and Roberts, L. (1992) Teaching social and coping skills. In Birchwood, M. and Tarrier, N. (Eds.), Innovations in the psychological management of schizophrenia. John Wiley, Chichester, pp. 103-114.
38. Vaccaro, J.V. Young, A.S. and Glynn, S. (1993) Community-based care of individuals with schizophrenia: combining psychosocial and pharmacologic therapies. Psychiatr. Clin. North Am. 16, 387-399.
39. Van Weeghel, J. and Zeelen, J. (1991) Arbcidsrehabilitalie. Lemma, Utrecht.
40. Westermeyer, J.F. and Harrow, M. (1988) Course and outcome in schizophrenia. In Tsuang. M.T. and Simpson. J.C. (Eds.), Handbook of schizophrenia. Elsevier, Amsterdam, pp. 263-280.
41. Wyatt, R. (1991) Neuroleptics and the natural course of schizophrenia. Schizophr. Bull. 17, 325-351.